memo (2018) 11:84
Update and clinical highlights presented at the
2017 American Society of Hematology Meeting
Received: 2 May 2018
Accepted: 22 May 2018
Published online: 1 June 2018
© Springer-Verlag GmbH Austria, part of Springer Nature 2018
At the 2017 American Society of Hematology (ASH)
meeting partly standards-changing data in the treat-
ment of hematological malignancies were presented.
More than 5000 scientiﬁc abstracts are submitted each
year and more than 3000 abstracts are accepted for
oral and poster presentations through an extensive
peer review process. In this issue of memo ﬁve hema-
tologists summarized their personal highlights in their
respective areas of expertise.
My personal highlight was the presentation of the
MURANO study. The clear superiority of a targeted
therapy changes practical behavior with immune-
chemotherapy having no place in second-line treat-
ment of chronic lymphocytic leukemia (CLL) any-
more. Moreover, the authors summarize important
data about the combination of venetoclax and ibruti-
In addition to CLL, reviews about important de-
velopments in the treatment of indolent lymphoma,
multiple myeloma, CML, and AML are provided in this
Concerning indolent lymphoma, Dr. Gilles Salles
presented a 10-year update of the PRIMA trial, con-
ﬁrming a progression-free survival (PFS) beneﬁt for
Dr. D. Heintel (
Wilhelminenspital, Montleartstraße 37, 1160 Vienna, Austria
rituximab maintenance following R-CHOP induction.
The median PFS was 10.5 vs. 4 years (p < 0.0001).
Also in mantle cell lymphoma, the superiority of
rituximab maintenance was proven.
In ﬁt patients with multiple myeloma, eligible for
autologous stem cell transplantation, new induction
regimens showed high minimal residual disease neg-
Regarding CML interesting data regarding novel
TKIs or treatment duration of imatinib were pre-
In the treatment of AML novel promising sub-
stances enrich the spectrum of therapy choices which
also impressed the audience at the last ASH meeting.
Conﬂict of interest D. Heintel receives honoraria from Abb-
vie, Celgene, Gilead, Janssen, MSD, Roche, Takeda.
For latest news from interna-
tional oncology congresses see:
84 Update and clinical highlights presented at the 2017 American Society of Hematology Meeting